Merck's Upside Potential: Beyond The Keytruda Cliff
29/6 17:29
While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month, we discussed how Keytruda is a ticking time bomb for Merck stock. In this analysis,...